CHA₂DS₂-VASc was developed to be more inclusive of common stroke risk factors/modifiers. Numerous validation studies have shown that CHA₂DS₂-VASc is as good as - or possibly better - than CHADS₂ at predicting high risk patients, but CHA₂DS₂-VASc is certainly best at predicting the “low risk” patients.

In general, a CHA 2 DS 2 -VASc score of 1 should warrant strong consideration for full oral anticoagulation. 2 The one exception, however, is in patients who have a score of 1 due to gender alone. In these patients (female < 65 years old without other risk factors), antithrombotic therapy should not be given.

The CHADS2 score and its updated version, the CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in people with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke.

Van den Ham et al. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation. JACC. 2015.

The CHA2DS2-Vasc calculator helps you assess the stroke risk in your patient with atrial fibrillation.

Aug 14, 2012 · Given the need to be more inclusive of common stroke risk factors, the CHA 2 DS 2 -VASc score 14 has been proposed (Table 2), with scores ranging from 0 to 9.

It is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. A high CHADS 2 score corresponds to a greater risk of stroke, while a low CHADS 2 score corresponds to a lower risk of stroke.

Mar 17, 2025 · In patients with atrial fibrillation (AF) or atrial flutter, the CHA 2 DS 2 -VASc score is recommended by AHA/ACC/HRS and ESC Guidelines for assessment of stroke risk 1 2.

<img alt="This icon serves as a link to download the eSSENTIAL Accessibility assistive technology app for individuals with physical disabilities.

CHA2DS2-VASc score 1,2: Clinical prediction rule for assessing the risk of stroke in patients with non-valvular atrial fibrillation. The result can be used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy.